$INSM · INSMED Inc
Insmed filed an 8-K on October 5, 2026, announcing the departure of CFO Sara Bonstein effective October 30, 2026, under Item 5.02. The company stated the separation is not related to any disagreement on accounting practices, financial statements, internal controls, or operations. The filing also includes Item 7.01 Regulation FD disclosure, with a press release attached as Exhibit 99.1 that provides Q3 2026 guidance information.
- CFO Sara Bonstein is separating from Insmed effective October 30, 2026, with a successor search underway.
- The company explicitly states the departure is not related to any disagreement on accounting, financial statements, internal controls, or 8K
- The 8-K also includes Item 7.01 Regulation FD disclosure with Q3 2026 guidance information in the attached press release.
- Bonstein will receive severance benefits under Section 6.e of her Amended and Restated Employment Agreement dated April 1, 2022.
- The press release (Exhibit 99.1) containing Q3 guidance was not filed, only furnished under Reg FD.
Extended-hours trading shows INSM at $108.59, down 2.28% from the regular close of $111.12, indicating a negative initial reaction to the CFO departure news on a $24.09B market cap company.
A sudden CFO exit at a $24B biotech, even when framed as amicable, raises governance questions — and the simultaneous Q3 guidance drop doubles the event risk.
CFO turnover at mid-cap biopharma companies often draws heightened scrutiny given the complexity of drug revenue recognition, R&D capitalization, and pipeline valuation disclosures.
CFO departures at commercial-stage biotechs can signal undisclosed financial stress or strategic disagreements, even when the filing disclaims accounting disputes. The Q3 guidance embedded in the press release could contain negative surprises not yet priced in.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.